|
Miraculins CEO Christopher J. Moreau recently told the Company's story to Leonard Zehr from Biotuesday.ca and the conversation can be found here:
http://biotuesday.ca/2010/03/02/in-conversation-with-christopher-moreau/
Read More
|
|
WINNIPEG, Manitoba – February 9, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 7,150,000 units (“Units”) at a price of $0.07 per Unit for gross proceeds of up to $500,500. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”).
Read More
|
|
Agreement Includes Fee From Inverness to Acquire Exclusive Option to License Worldwide Rights
WINNIPEG, Manitoba – January 7, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has entered into a partnership with Inverness Medical Innovations, Inc. (NYSE:IMA), a global leader in the convergence of medical diagnostic testing and health management, to advance and commercialize Miraculins’ preeclampsia technology.
Read More
|
|
WINNIPEG, Manitoba – June 18, 2009 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, has closed its previously announced private placement offering (the "Offering") with aggregate gross proceeds to the Company of $400,000 from the sale of 8,000,000 units ("Units") at a price of $0.05 per Unit. Each Unit is comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a "Warrant"). Each Warrant entitles the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued. The net proceeds of the Offering shall be used for research and development and working capital purposes. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws and the policies of the TSX Venture Exchange.
Read More
|
|
WINNIPEG, Manitoba – June 12, 2009 - Miraculins Inc. (TSX-V:MOM), a company focused on developing and commercializing medical and diagnostic tests for unmet clinical needs, is pleased to announce that it has increased the current private placement offering (the “Offering”), first reported on April 27, 2009, from a maximum of 5,000,000 units (“Units”) to 8,000,000 Units, for total gross proceeds of up to $400,000. As previously announced, each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued.
Read More
|
|
|